Investments, Funding & Disinvestment

Once fully operational, the manufacturing plant is expected to create direct employment opportunities for more than 500 people.

Hetronifly is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody that has already received regulatory approval in China for treating several solid tumor types.

Once the transaction successfully closes, the combined company plans to operate under the PrimeGen US name or through a successor entity.

Within the context of AI and automation, these leaders anticipate emerging technologies, design future workflows, and guide laboratories toward digital maturity through strategic vision.

The company plans to utilize two key facilities for this production: its Oxford, United Kingdom site and its Durham, North Carolina location.

The deal centers on one of SanegeneBio’s innovative RNAi programs and grants Genentech exclusive worldwide rights to develop and bring the treatment to market.

The new Irish facility aims to accelerate innovation and bring next-generation diagnostic capabilities to hospitals and laboratories worldwide.

The divestment positions Halo to focus on expanding into more complex drug-product manufacturing services while strengthening its presence in the sterile CDMO market.

Unlike traditional bypass surgery, which relies on a heart-lung machine, the off-pump approach allows surgeons to operate while the patient’s heart continues to beat naturally.

HC21 UK will showcase its capabilities at the ABHI UK Pavilion located in Hall 2, where members of its Irish management team will join forces to demonstrate the group’s comprehensive approach to market expansion.